Emerging Stocks Down Under 24 November 2020: Rhythm Biosciences, Hazer Group, Skyfii

Rhythm Biosciences: A Seriously Better Alternative

In today’s edition of Emerging Stocks Down Under, the Melbourne-based Rhythm Biosciences, which is developing a next-generation diagnostic for colorectal cancer, has enjoyed a nice re-rating lately. Back on 6 August, you could buy this stock for just 7.8 cents. By 12 November it had made it to 42 cents. That’s because the data for the diagnostic has looked very good so far, and there’s likely more where that came from.

Also in today’s edition, a look at hydrogen and graphite producer the Hazer Group (ASX: HZR) and venue analytics developer SkyFii (ASX: SKF).

Get access to all editions through a 30-day FREE TRIAL. No credit card required and the trial expires automatically.

SUBSCRIBE NOW

Click here to read the previous edition of Emerging Stocks Down Under published 17 November 2020

For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter